Sign in →

Test Code FARV2 Nasopharyngeal- Respiratory Pathogen Panel with COVID-19, PCR (Filmarray)

Additional Codes

Epic: LAB15532

Specimen Required

Specimen Type: Nasopharyngeal Swab

Collection Container/Type

Preferred: Viral transport media (VTM)

Acceptable: Universal transport media (UTM)

Submission Container/Tube: VTM or UTM collection media

Specimen Volume: Swab

Collection Instructions: 

  1. Nasopharyngeal Swab- Collect according to standard technique and immediately place swab into 3ml Viral transport media (VTM) or Universal transport media (UTM). 


Specimen Stability

Room temperature: 4 hours

Refrigerated: 2 days

Frozen: Unacceptable

Reference Range

See laboratory report.

Rejection Due To

Specimen not received in appropriate transport container or at appropriate temperature.

Report Available

1-2 days

Method Name

Real-time, nested multiplexed polymerase chain reaction using the BioFire Respiratory Panel 2.1 (RP2.1)


Real-time, nested multiplexed polymerase chain reaction test designed to simultaneously identify nucleic acids from 22 different viruses and bacteria associated with respiratory tract infection from a single nasopharyngeal swab. Targets include: Adenovirus, Coronavirus 229E, Coronavirus HKU1, Coronavirus NL63, Coronavirus OC43, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Human Metapneumovirus, Human Rhinovirus/Enterovirus, Influenza A, Influenza B, Parainfluenza Virus 1, Parainfluenza Virus 2, Parainfluenza Virus 3, Parainfluenza Virus 4, Respiratory Syncytial Virus, Bordetella parapertussis, Bordetella pertussis, Chlamydia pneumoniae, Mycoplasma pneumoniae


This assay cannot differentiate between Rhinovirus/Enterovirus. If necessary for patient care, a positive result for Rhinovirus/Enterovirus may be followed-up using an alternate method. This assay should not be used if B. pertussis infection is specifically suspected as it is less sensitive than other alternatives. If suspected, ensure that B. pertussis specific testing is ordered. Recent administration of a nasal influenza vaccine may cause false positive results for Influenza A and/or Influenza B.
Viral and bacterial nucleic acids may persist even though no viable organism is present. Detection of nucleic acid does not imply that the corresponding organisms are infectious or are the causative agents of clinical symptoms. A negative result does not exclude the possibility of viral or bacterial infection and should not be used as the sole basis for patient management decisions. Assay performance characteristics may vary with circulating strains and this assay may not be able to distinguish between existing viral strains and new variants as they emerge. Invalid results may be due to inhibiting substances in the specimen and recollection should occur.

Day(s) Performed